Articles written by Tiziana Life Sciences - Benzinga

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

NEW YORK, September 26, 2023 – Tiziana Life Sciences Ltd. (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with principal i

Poised For Growth? This Biotech Is Close To Beginning Key Phase 2a Study With Its Lead Candidate

Tiziana Life Sciences (NASDAQ: TLSA) is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and lung diseases.

Sponsored

Study Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance

The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)” FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer’s Disease

Tiziana Life Sciences Announces Anti-CD3 mAb Research For The Treatment Of Alzheimer's Disease To Be Presented By Dr. Howard Weiner At The International Conference On Alzheimer's And Parkinson's Disease And Related Neurological Disorders Conference In Sweden

Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammation may be synergistic to existing treatments in AD

Tiziana Life Sciences To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological disease Tiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with non-active SPMS